Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

11065	Companies
242740	Keywords
170980	Articles
130687	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

PRESS RELEASE

published on 07/09/2026 at 08:00, 2 months 14 days ago

Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism
Pentixapharm Holding AG granted FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor diagnostic candidate in primary aldosteronism. Fast Track streamlines regulatory process & interaction with FDA

FDA Fast Track Pentixapharm Primary Aldosteronism Regulatory Milestone Diagnostic Candidate
BRIEF

published on 07/09/2026 at 07:08, 2 months 15 days ago

Pentixapharm Holding AG obtient la procédure accélérée de la FDA pour son candidat diagnostic

Procédure Accélérée De La FDA Aldostéronisme Primaire Examen Réglementaire Étude PANDA [68Ga]Ga-PentixaPour
BRIEF

published on 07/09/2026 at 07:08, 2 months 15 days ago

Pentixapharm Holding AG Secures FDA Fast Track for Diagnostic Candidate

FDA Fast Track Primary Aldosteronism Regulatory Review PANDA Study [68Ga]Ga-PentixaFor
PRESS RELEASE

published on 07/09/2026 at 07:03, 2 months 15 days ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism
Pentixapharm Holding AG receives FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor for subtyping of Primary Aldosteronism, allowing more efficient regulatory review process

FDA Fast Track Primary Aldosteronism Pentixapharm Holding AG [68Ga]Ga-PentixaFor Subtyping
BRIEF

published on 07/01/2026 at 15:32, 2 months 22 days ago

Pentixapharm lance une levée de fonds pour financer la phase 3 de son essai clinique PANDA et sa croissance aux États-Unis.

Augmentation De Capital Pentixapharm Émission De Droits Expansion Américaine PANDA Phase 3
BRIEF

published on 07/01/2026 at 15:32, 2 months 22 days ago

Pentixapharm Initiates Capital Expansion for PANDA Phase 3 and U.S. Growth

Capital Increase Rights Issue U.S. Expansion Pentixapharm PANDA Phase 3
PRESS RELEASE

published on 07/01/2026 at 15:27, 2 months 22 days ago

Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion
Pentixapharm launches rights issue to fund PANDA Phase 3 study and U.S. expansion, major shareholder commits to full exercise of subscription rights

Capital Increase Rights Issue U.S. Expansion Pentixapharm PANDA Phase 3
BRIEF

published on 07/01/2026 at 12:10, 2 months 22 days ago

Pentixapharm Holding AG Plans Rights Issue to Raise EUR 20.4 Million

Capital Increase Rights Issue Subscription Price PANDA Phase 3 Study Eckert Wagniskapital
BRIEF

published on 07/01/2026 at 12:10, 2 months 22 days ago

Pentixapharm Holding AG prévoit une augmentation de capital par émission de droits pour lever 20,4 millions d'euros.

Augmentation De Capital Émission De Droits Prix De L'abonnement Eckert Wagniskapital Étude PANDA De Phase 3
PRESS RELEASE

published on 07/01/2026 at 12:05, 2 months 22 days ago

EQS-Adhoc: Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights
Pentixapharm Holding AG resolves on rights issue worth up to EUR 20.4 million; Eckert Wagniskapital to fully exercise subscription rights for new shares, supporting corporate development and PANDA Phase 3 study

Rights Issue Subscription Rights Pentixapharm Holding AG PANDA Phase 3 Study Eckert Wagniskapital

Accesswire

Published on 09/23/2026 at 22:00, 9 hours 33 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 13 hours 8 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 15 hours 51 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 17 hours 2 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 17 hours 3 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

EQS Group

Published on 09/24/2026 at 07:15, 17 minutes ago

EQS-Adhoc: Shelly Group SE enters into Investment Agreement with Schneider Electric SE
Published on 09/24/2026 at 07:00, 32 minutes ago

Cembra prévoit son nouveau siège social à Baden
Published on 09/24/2026 at 07:00, 32 minutes ago

Cembra plans new headquarters in Baden
Published on 09/24/2026 at 07:00, 33 minutes ago

flatexDEGIRO sets new cost benchmark for Germany’s Retirement Savings Account (Altersvorsorgedepot)
Published on 09/24/2026 at 07:00, 33 minutes ago

Europe’s small & mid caps: Opportunities remain intact in a new investment era

Les Echos

Published on 09/24/2026 at 07:00, 33 minutes ago

bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
Published on 09/24/2026 at 07:00, 33 minutes ago

bioMérieux lance SPINCHIP® hs-cTnl, une innovation majeure pour le dosage hypersensible de la troponine I cardiaque et l’accélération de la prise en charge des urgences cardiaques
Published on 09/23/2026 at 19:46, 11 hours 46 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 11 hours 46 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 12 hours 18 minutes ago

Robust performance from Investments and continued execution of the strategy

View all LES ECHOS COMFI WIRE